Perfusão Arterial Invertida em Gémeos

A perfusão arterial invertida em gémeos foi descrita pela primeira vez em 1533 por Benedetti. Esta patologia também é conhecida como TRAP (Twin Reversed Arterial Perfusion) ou monstro acárdico. É uma patologia que ocorre na gravidez múltipla monocoriónica caracterizada pela presença de um gémeo dador e outro receptor, anómalo, muitas vezes sem estrutura morfológica definida. É uma situação rara (1/35000 partos) mas grave, podendo ocorrer a morte do gémeo normal em cerca de 50 (¹,²,³)- 75% (¹,²) dos casos, consoante as séries consultadas. Foi efectuado um estudo retrospectivo dos casos de gémeos acardicos vigiados na Consulta de Gravidez Múltipla e no Centro de Diagnóstico Pré-Natal da Maternidade Dr. Alfredo da Costa, entre os anos de 1994 e 2002. Num total de 597 gravidezes múltiplas, 120 caracterizadas como monocoriónicas, foram diagnosticados três casos.

Low Dose Thalidomide for Treatment of Resistant Discoid Lupus Erythematosus. A Case Report

Discoid lupus erythematosus (DLE) is a chronic, indolent, disfiguring disease that is characterized by scaly, erythematous, disk-shaped patches and plaques followed by atrophy, scarring and depigmentation. In a small number of patients, it is refractory to standard therapies. In several studies, thalidomide has been reported to be an effective treatment in those cases. The most fearful side effects are teratogenicity and neuropathy. Adequate counseling and vigilance must be given to the patients. We report a 45-year-old Portuguese woman who presented with a 20-year history of severe facial and scalp DLE confirmed by histopathology. For several years, it failed to respond to several therapies, including topical, intralesional and oral corticosteroids, hydroxychloroquine, methotrexate, azathioprine and topical tacrolimus. Thalidomide was initiated at a dosage of 50mg/day and the skin lesions had improved dramatically after three weeks with complete clinical remission. Two months later, the dose was reduced to 50mg, five days per week without disease rebound. The patient´s concomitant medications during the treatment included sunscreen, hydroxycholoroquine, enoxaparin and aspirin to prevent thromboembolic events. Pregnancy testing, routine laboratory and electrocardiography were performed at regular intervals for safety monitoring and the results were within normal limits. Only minor side effects as nausea, constipation and somnolence were noted, however, they improved with dose reduction. Our data confirm that thalidomide therapy is an alternative or adjunctive treatment for patients with severe, chronic DLE that is refractory to standard therapies. In this patient, low-dose thalidomide was an effective treatment with minimal side effects.